The abstract is read at the publisher; the summary is JClub's.
Antisecretory factor (Salovum®) reduced 30-day mortality in adults with isolated severe traumatic brain injury, from 39% to 20% in a Cape Town phase II trial.
- Why it matters: Isolated severe TBI has high mortality and long-term morbidity, particularly in low- and middle-income countries, and prior experimental therapies lacked robust clinical trial evidence.
- What they did: In a prospective, double-blind, placebo-controlled phase 2 study (NCT03339505) at a tertiary trauma center in Cape Town, adults with Glasgow Coma Score 6–8 received weight-based Salovum® or placebo via nasogastric tubing for up to 5 days.
- The result: The treatment group showed a relative risk ratio of 0.52 (confidence interval 0.271–0.997) with P=0.040, while therapy intensity level and ICP were similar and no significant adverse events were noted.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.